140 related articles for article (PubMed ID: 35618599)
21. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy.
Tanaka T; Kawashima A; Rangel LJ; Schulte PJ; Froemming AT; King BF; Mynderse LA; Karnes RJ
J Urol; 2022 May; 207(5):1038-1047. PubMed ID: 34981952
[TBL] [Abstract][Full Text] [Related]
22. Routinely reported 'equivocal' lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes.
Galiabovitch E; Hovens CM; Peters JS; Costello AJ; Battye S; Norden S; Ryan A; Corcoran NM
BJU Int; 2017 Apr; 119(4):567-572. PubMed ID: 27431748
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
Harmon SA; Gesztes W; Young D; Mehralivand S; McKinney Y; Sanford T; Sackett J; Cullen J; Rosner IL; Srivastava S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Dobi A; Sesterhenn IA; Turkbey B
Radiology; 2021 Jun; 299(3):613-623. PubMed ID: 33847515
[TBL] [Abstract][Full Text] [Related]
24. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
25. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
Liauw SL; Pitroda SP; Eggener SE; Stadler WM; Pelizzari CA; Vannier MW; Oto A
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):378-84. PubMed ID: 22717242
[TBL] [Abstract][Full Text] [Related]
27. Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings.
Wibmer AG; Chaim J; Lakhman Y; Lefkowitz RA; Nincevic J; Nikolovski I; Sala E; Gonen M; Carlsson SV; Fine SW; Zelefsky MJ; Scardino P; Hricak H; Vargas HA
J Urol; 2021 Apr; 205(4):1055-1062. PubMed ID: 33207133
[TBL] [Abstract][Full Text] [Related]
28. Low detectable prostate specific antigen after radical prostatectomy--treat or watch?
Koulikov D; Mohler MC; Mehedint DC; Attwood K; Wilding GE; Mohler JL
J Urol; 2014 Nov; 192(5):1390-6. PubMed ID: 24859441
[TBL] [Abstract][Full Text] [Related]
29. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract][Full Text] [Related]
30. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
31. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with
Sobol I; Zaid HB; Haloi R; Mynderse LA; Froemming AT; Lowe VJ; Davis BJ; Kwon ED; Karnes RJ
J Urol; 2017 Jan; 197(1):129-134. PubMed ID: 27449262
[TBL] [Abstract][Full Text] [Related]
32. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
33. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both.
Suresh N; Teramoto Y; Wang Y; Miyamoto H
Urol Oncol; 2022 May; 40(5):193.e7-193.e14. PubMed ID: 35410776
[TBL] [Abstract][Full Text] [Related]
35. Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.
Aminsharifi A; Polascik TJ; Tsivian M; Schulman A; Tsivian E; Tay KJ; Elshafei A; Jones JS
Clin Genitourin Cancer; 2018 Oct; 16(5):e1073-e1076. PubMed ID: 30054221
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of CE-MRI in detecting local recurrence after radical prostatectomy.
Coppola A; Platania G; Ticca C; De Mattia C; Bortolato B; Palazzi MF; Vanzulli A
Radiol Med; 2020 Jul; 125(7):683-690. PubMed ID: 32078119
[TBL] [Abstract][Full Text] [Related]
37. Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy.
Eineluoto JT; Sandeman K; Pohjonen J; Sopyllo K; Nordling S; Stürenberg C; Malén A; Kilpeläinen TP; Santti H; Petas A; Matikainen M; Pellinen T; Järvinen P; Kenttämies A; Rannikko A; Mirtti T
Eur Urol Focus; 2021 Nov; 7(6):1316-1323. PubMed ID: 32620540
[TBL] [Abstract][Full Text] [Related]
38. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
Wachter S; Tomek S; Kurtaran A; Wachter-Gerstner N; Djavan B; Becherer A; Mitterhauser M; Dobrozemsky G; Li S; Pötter R; Dudczak R; Kletter K
J Clin Oncol; 2006 Jun; 24(16):2513-9. PubMed ID: 16636343
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
[TBL] [Abstract][Full Text] [Related]
40. Prostate MRI evolution in clinical practice: Audit of tumour detection and staging versus prostatectomy with staged introduction of multiparametric MRI and Prostate Imaging Reporting and Data System v2 reporting.
Raeside M; Low A; Cohen P; Sutherland P; Gormly K
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):487-494. PubMed ID: 30951248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
